Advertisement

The Use of OKT3 in Clinical Transplantation

  • Daniel Abramowicz
  • Michel Goldman
Part of the Medical Intelligence Unit book series (MIU.LANDES)

Abstract

OKT3 is a murine monoclonal antibody of the IgG2a isotype recognizing the ε chain of the CD3 complex, a series of proteins tightly linked to the individual T-cell receptor present on all mature T cells.1,2 OKT3 has been produced by immunization of mice with human T cells in 1979.1 The discovery that OKT3 blocked in vitro the lytic activity of cytotoxic T cells3,4 led to its use in renal allograft rejection,5 even before the molecular structure recognized on T lymphocytes was identified. Since then, extensive data have shown that OKT3 is probably the most potent drug available to treat rejection of organ allografts.6–11 In addition, as avoidance of rejection in the early post-transplant period might be a determining factor in the achievement of successful long-term allograft survival, OKT3 has been evaluated as an inductive agent in renal transplantation.6–12 In this review, we first define the mechanisms of action of OKT3. We then describe the main studies that established its efficacy both for the treatment and the prevention of renal allograft rejection. Finally, we discuss its main side effects and strategies to prevent them.

Keywords

Graft Survival Transplant Proc Renal Allograft Rejection Cytokine Release Syndrome Acute Renal Allograft Rejection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kung P, Goldstein G, Reinherz E, Schlossman S. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979; 206: 347–349.PubMedGoogle Scholar
  2. 2.
    Acuto O, Reinherz EL. The human T-cell receptor. Structure and function. N Engl J Med 1985; 312: 1100–11.PubMedGoogle Scholar
  3. 3.
    Chang TW, Kung PC, Gingras SP, Goldstein G. Does OKT3 reacts with an antigen-recognition structure on human T cells? Proc Natl Acad Sci USA 1981; 78: 1805–1808.PubMedGoogle Scholar
  4. 4.
    Platsoucas CD, Good RA. Inhibition of cell-mediated cytotoxicity by monoclonal antibodies to human T cell antigens. Proc Natl Acad Sci USA 1981; 78: 4500–4504.PubMedGoogle Scholar
  5. 5.
    Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP, Tolkoff-Rubin N, Rubin RH, Herrin JT, Russell PS. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32: 535–539.PubMedGoogle Scholar
  6. 6.
    Kreis H, Legendre C, Chatenoud L. OKT3 in organ transplantation. Transplant Rev 1991; 5: 181–199.Google Scholar
  7. 7.
    Parlevliet KJ, Schellekens PT. Monoclonal antibodies in renal transplantation: a review. Transpl Int 1992; 5: 234–46.PubMedGoogle Scholar
  8. 8.
    DeMattos A, Norman DJ. OKT3 for treatment of rejection in renal transplantation. Clin Transpl 1993; 7.Google Scholar
  9. 9.
    Peters H. The use of OKT3 in recipients of pancreatic, pulmonary, and bone marrow allografts. Clin Transplant 1993; 7: 414–421.Google Scholar
  10. 10.
    Hockerstedt K. Treatment and prevention of liver allograft rejection with OKT3. Clin Transplant 1993; 7: 403–413.Google Scholar
  11. 11.
    Renlund D. OKT3 for induction of immunosuppression and treatment of rejection in cardiac allograft recipients. Clin transplant 1993; 7: 393–402.Google Scholar
  12. 12.
    Abramowicz D, Goldman M. OKT3 for induction of immunosup-pression in renal transplantation. Clin Transpl 1993; 7: 382–392.Google Scholar
  13. 13.
    Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC, Hansen WP, Delmonico FL, Russell PS. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981; 305: 308–314.PubMedGoogle Scholar
  14. 14.
    Chatenoud L, Baudrihaye JM, Kreis H, Bach JF. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982; 12: 979–982.PubMedGoogle Scholar
  15. 15.
    Dustin M, Springer T. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 1989; 341: 619–624.PubMedGoogle Scholar
  16. 16.
    Bergese SD, Pelletier RP, Ohye RG, Vallera DA, Orosz CG. Treatment of mice with anti-CD3 mAb induces endothelial vascular cell adhesion molecule-1 expression. Transplantation 1994; 57: 711–7.PubMedGoogle Scholar
  17. 17.
    Raasveld MH, Bemelman FJ, Schellekens PT, Hack CE. Complement activation during OKT3 treatments possible explanation for respiratory side effects. Kidney Int 1993; 43: 1140–9.PubMedGoogle Scholar
  18. 18.
    Russell JH, Rush BJ, Abrams SI, Wang R. Sensitivity of T cells to anti-CD3-stimulated suicide is independent of functional pheno-type. Eur J Immunol 1992; 22: 1655–8.PubMedGoogle Scholar
  19. 19.
    Wong J, Eylath A, Ghobrial I, Colvin R. The mechanisms of anti-CD3 monoclonal antibodies: mediation of cytolysis by inter-T cell bridging. Transplantation 1990; 50: 683–689.PubMedGoogle Scholar
  20. 20.
    Tsoukas C, Fox R, Slovin S et al. Molecular interactions in human T-cell mediated cytotoxicity to EBV. I. Blocking of effector cell function by monoclonal antibody OKT3. Cell Immunol 1982; 69: 113–119.PubMedGoogle Scholar
  21. 21.
    Landegren U, Ramstedt U, Axberg I, Ullberg M, Jondal M, Wigzell H. Selective inhibition of human T cell cytotoxicity at levels of target recognition or initiation of lysis by monoclonal OKT3 and Leu-2a antibodies. J Exp Med 1982; 155: 1579–1584.PubMedGoogle Scholar
  22. 22.
    Tsoukas C, Carson D, Fong S, Vaughan J. Molecular interactions in human T-cell mediated cytotoxixity to EBV. II. Monoclonal antibody OKT3 inhibits a post-killer-target recognition/adhesion step. J Immunol 1982; 129: 1421–1425.PubMedGoogle Scholar
  23. 23.
    Nau GJ, Moldwin RL, Lancki DW, Kim DK, Fitch FW. Inhibition of IL 2-driven proliferation of murine T lymphocyte clones by supraoptimal levels of immobilized anti-T cell receptor monoclonal antibody. J Immunol 1987; 139: 114–122.PubMedGoogle Scholar
  24. 24.
    Webb S, Sprent J. Downregulation of T cell responses by antibodies to the T cell receptor. J Exp Med 1987; 165: 584–589.PubMedGoogle Scholar
  25. 25.
    Williams ME, Lichtman AH, Abbas AK. Anti-CD3 antibody induces unresponsiveness to IL-2 in Th1 clones but not in Th2 clones. J Immunol 1990; 144: 1208–1214.PubMedGoogle Scholar
  26. 26.
    Jenkins MK, Chen C, Jung G, Mueller DL, Schwartz RH. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol 1990; 144: 16–22.PubMedGoogle Scholar
  27. 27.
    Schwartz R. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349–1356.PubMedGoogle Scholar
  28. 28.
    Davis LS, Wacholtz MC, Lipsky PE. The induction of T cell unresponsiveness by rapidly modulating CD3. J Immunol 1989; 142: 1084–1094.PubMedGoogle Scholar
  29. 29.
    Pantaleo G, Olive D, Poggi A, Pozzan T, Moretta L, Moretta A. Antibody-induced modulation of the CD3/T cell receptor complex causes T cell refractoriness by inhibiting the early metabolic steps involved in T cell activation. J Exp Med 1987; 166.Google Scholar
  30. 30.
    Dubois PM, Andris F, Shapiro RA, L.K. G, Kaufman M, Urbain J, Ledbetter JA, Leo O. T cell long-term hyporesponsiveness follows antigen receptor engagement and results from defective signal transduction. Eur J Immunol 1994; 24.Google Scholar
  31. 31.
    Williams ME, Shea CM, Lichtman AH, Abbas AK. Antigen receptor-mediated anergy in resting T lymphocytes and T cell clones. J Immunol 1992; 149: 1921–1926.PubMedGoogle Scholar
  32. 32.
    Wolf H, Müller Y, Salmen S, Wilmanns W, G. J. Induction of anergy in resting human T lymphocytes by immobilized anti-CD3 antibodies. Eur J Immunol 1994; 24: 1410–1417.PubMedGoogle Scholar
  33. 33.
    Anasetti C, Tan P, Hansen JA, Martin PJ. Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen. J Exp Med 1990; 172: 1691–1700.PubMedGoogle Scholar
  34. 34.
    Mackie JD, Pankewycz OG, Bastos MG, Kelley VE, Strom TB. Dose-related mechanisms of immunosuppression mediated by murine anti-CD3 monoclonal antibody in pancreatic islet cell transplantation and delayed-type hypersensitivity. Transplantation 1990; 49: 1150–1154.PubMedGoogle Scholar
  35. 35.
    Nicolls MR, Aversa GG, Pearce NW, Spinelli A, Berger MF, Gurley KE, Hall BM. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 1993; 55: 459–68.PubMedGoogle Scholar
  36. 36.
    Heidecke CD, Hancock WW, Jakobs F, Westerholt S, Sewzcik T, Deusch K, Zanti N, Kurrle R, Kupiec-Weglinski J. TCRa/b targeted therapy in the rat: pretreatment with R73 monoclonal antibody induces profound immunological anergy and long-term allograft survival. Transplant Proc 1993; 25: 540–542.PubMedGoogle Scholar
  37. 37.
    Knight RJ, Kurrle R, Stepkowski S, Serino F, Chou TC, Kahan BD. Synergistic immunosuppressive actions of cyclosporine with a mouse anti-rat a/b-T cell receptor monoclonal antibody. Transplantation 1994; 57: 1544–1548.PubMedGoogle Scholar
  38. 38.
    A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med 1985; 313: 337-42.Google Scholar
  39. 39.
    Deierhoi MH, Barber WH, Curtis JJ, Julian BA, Luke RG, Hudson S, Barger BO, Diethelm AG. A comparison of OKT3 monoclonal antibody and corticosteroids in the treatment of acute renal allograft rejection. Am J Kid Dis 1988; XI: 86–89.Google Scholar
  40. 40.
    Tesi RJ, Elkhammas EA, Henry ML, Ferguson RM. OKT3 for primary therapy of the first rejection episode in kidney transplants. Transplantation 1993; 55: 1023–9.PubMedGoogle Scholar
  41. 41.
    Suthanthiran M, Wiebe ME, Stenzel KH. Effect of immunosuppressants on OKT3 associated T cell activation:clinical implications. Kidney Int 1987; 32: 362–367.PubMedGoogle Scholar
  42. 42.
    De Mattos AM, Norman DJ. OKT3 for treatment of rejection in renal transplantation. Clin Transplant 1993; 7: 374–381.Google Scholar
  43. 43.
    Hricik D, Mayes J, Schulak J. Inhibition of anti-OKT3 antibody generation by cyclosporine-results of a prospective, randomized trial. Transplantation 1990; 50: 237–240.PubMedGoogle Scholar
  44. 44.
    Hesse UJ, Wienand P, Baldamus C, Ams W. Preliminary results of a prospectively randomized trial of ALG Vs OKT3 for steroid-resistant rejection after renal transplantation in the early postoperative period. Transplant Proc 1990; 22: 2273–2274.PubMedGoogle Scholar
  45. 45.
    Alamartine E, Bellakoul R, Berthoux F. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts. Transplant Proc 1994; 26: 273–4.PubMedGoogle Scholar
  46. 46.
    Blümke M, Kirste G, Wanner U, Wilms H. Single center randomized trial using ATG v OKT3 treatment in steroid resistant rejection crises after kidney transplantation. Transplant Proc 1989; 21: 1747.PubMedGoogle Scholar
  47. 47.
    Delaney VB, Campbell WG, Nasr SA, McCue PA, Warshaw B, Whelchel JD. Efficacy of OKT3 monoclonal antibody therapy in steroid-resistant, predominantly vascular acute rejection. Transplantation 1988; 45: 743–748.PubMedGoogle Scholar
  48. 48.
    Schroeder TJ, Weiss MA, Smith RD, Stephens GW, M.R. F. The efficacy of OKT3 in vascular rejection. Transplantation 1991; 51: 312–315.PubMedGoogle Scholar
  49. 49.
    Colon S, Pouteil-Noble C, Ecochard R, Lacavalerie B, Touraine J. Lésions histologiques pronostiquées de la perte du greffon lors du premier rejet. Etude cas-témoin. Néphrologie 1993; 14.Google Scholar
  50. 50.
    Benvenisty AI, Cohen D, Sregall MD, Hardy MA. Improved results using OKT3 as induction immunosuppression in renal allografts recipients with delayed graft function. Transplantation 1990; 49: 321–327.PubMedGoogle Scholar
  51. 51.
    Dafoe D, Bromberg J, Grossman R, Tomaszewski J, Zmijewski C, Perloff L, Naji A, Asplund M, Alfrey E, Sack M, Zellers L, Kearns J, Barker C. Renal transplantation despite a positive antiglobulin crossmatch with and without prophylactic OKT3. Transplantation 1991; 51: 762–768.PubMedGoogle Scholar
  52. 52.
    Abramowicz D, Goldman M, De Pauw L, Vanherweghem JL, Kinnaert P, Vereerstraeten P. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation—a single-center, prospective, randomized study. Transplantation 1992; 54: 433–7.PubMedGoogle Scholar
  53. 53.
    Norman DJ, Kahana L, Stuart FJ, Thistlethwaite JJ, Shield CE, Monaco A, Dehlinger J, Wu SC, Van HA, Haverty TP. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44–50.PubMedGoogle Scholar
  54. 54.
    Kahana L, Ackerman J, Lefor W et al. Use of Orthoclone OKT3 for prophylaxis of rejection and induction in initial nonfonction in kidney transplantation. Transplant Proc 1990; 22: 1755–1758.PubMedGoogle Scholar
  55. 55.
    Schroeder T, First M, Mansour R, Alexander J, Penn I. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Am J Kid Dis 1989; 14: 14–18.PubMedGoogle Scholar
  56. 56.
    Cecka JM, Gjertson D, Terasaki PI. Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups? Transplant Proc 1993; 25: 548–549.PubMedGoogle Scholar
  57. 57.
    Abramowicz D, Norman D, Goldman M, De Pauw L, Kinnaert P, Kahana L, Thistlethwaite J, Shield C, Monaco A, Vanherweghem J, Vereerstraeten P. OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine A: combined results from the prospective, randomized Belgian and U.S. studies. Transplant Proc 1995; In press:.Google Scholar
  58. 58.
    Lefrancois N, Raffaele P, Martinenghi S et al. Prophylactic polyclonal versus monoclonal antibodies in kidney and pancreas transplantation. Transpl Proc 1990; 22: 632–633.Google Scholar
  59. 59.
    Melzer J, D’allessandro A, Kalayoglu M, Pirsch J, Beizer F, Sollinger H. The use of OKT3 in combined pancreas-kidney allotransplantation. Transplant Proc 1990; 22: 634–635.PubMedGoogle Scholar
  60. 60.
    Steinmuller DR, Hayes JM, Novick AC, Streem SB, Hodge E, Slavis S, Martinez A, Graneto D, G. P. Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation. Transplantation 1991; 52: 67–71.PubMedGoogle Scholar
  61. 61.
    Knechtle SJ, Pirsch JD, Groshek M, Reed A, D’Alessandro AM, Kalayoglu M, Beizer FO, Sollinger HW. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation. Transplant Proc 1991; 23: 1581–1582.PubMedGoogle Scholar
  62. 62.
    Light JA, Jonsson J, Khawand N, Ali A, Aquino A, Currier CB, Romolo J, Gonzalez J, Korb S. Sequential Immunosuppression: Three years’ experience in 240 cadaveric renal transplants. Transplant Proc 1991; 23: 1032–1035.PubMedGoogle Scholar
  63. 63.
    Lloveras J, Puig JM, Oliveras A, Orfila A, Comerma I, Aubia J, Masramon J. Prophylaxis with a short course of OKT3 in renal transplantation: comparative analysis with recipients treated either with prophylactic ATG or with CyA. Transplant Proc 1992; 24: 43–4.PubMedGoogle Scholar
  64. 64.
    Frey DJ, Matas AJ, Gillingham KJ, Canafax D, Payne WD, Dunn DL, Sutherland DER, Najarian JS. Sequential therapy—a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 1992; 54: 50–56.PubMedGoogle Scholar
  65. 65.
    Grino JM, Castelao AM, Seron D, Gonzalez C, Galceran JM, Gil VS, Andres E, Mestre M, Torras J, Alsina J. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study. Am J Kidney Dis 1992; 20: 603–10.PubMedGoogle Scholar
  66. 66.
    Broyer M, Gagnadoux MF, Guest G, Arsan A, Beurton D, Revillon Y, Niaudet P. Prophylactic OKT3 monoclonal antibody versus Antilymphocyte Globulins: a prospective, randomized study in 148 first cadaver kidney grafts. Transplant Proc 1993; 25: 570–571.PubMedGoogle Scholar
  67. 67.
    Cole EH, Cattran DC, Farewell VT, Aprile M, Bear RA, Pei YP, Fenton SS, Tober JAL, Cardella CJ. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection. Transplantation 1994; 57: 60–67.PubMedGoogle Scholar
  68. 68.
    Hanto DW, Jendrisak MD, So SK, McCullough CS, Rush TM, Michalski SM, Phelan D, Mohanakumar T. Induction immuno-suppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial. Transplantation 1994; 57: 377–84.PubMedGoogle Scholar
  69. 69.
    Henell KR, Bakke A, Kenny TA, Kimball JA, Barry JM, Norman DJ. Degree of Modulation of cell-surface CD3 by anti-lymphocyte therapies. Transplant Proc 1991; 23: 1070–1071.PubMedGoogle Scholar
  70. 70.
    Norman D, Kimball J, Benett W, Shihab F, Batiuk T, Meyer M, Barry J. A prospective, double-blind, randomized study of high-versus low-dose OKT3 induction immunosuppression in cadaveric renal transplantation. Transplant Int 1994; 7: 356–361.Google Scholar
  71. 71.
    Parlevliet KJ, ten Berge RJM, Raasveld MHM, Surachno J, J.M. W, Schellekens PTA. Low-dose OKT3 induction therapy following renal transplantation: a controlled study. Nephrol Dial Transplant 1994; 9: 698–703.PubMedGoogle Scholar
  72. 72.
    Alloway R, Kotb M, Hathaway D, Ohman M, Strain S, Gaber A. The pharmacokinetic profile of standard and low-dose OKT3 induction immunosuppression in renal transplant recipients. Transplantation 1994; 58: 249–253.PubMedGoogle Scholar
  73. 73.
    Norman DJ, Barry JM, Benett WM, Munson JL, Meyer M, Henell K, Kimball J, Hubert B. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses. Transplant Proc 1991; 23: 1052–1054.PubMedGoogle Scholar
  74. 74.
    Schweizer RT, Roper L, Hull D, Bartus SA. Low-dose OKT3 for cadaveric renal transplantation. Transplant Proc 1992; 24: 2592–3.PubMedGoogle Scholar
  75. 75.
    Alloway RR, Kotb M, Gaber LW, Vera SR, Boskey F, Gaber AO. Standard versus low-dose OKT3 induction therapy of cadaveric renal transplants: comparison of outcome data versus OKT3 dose and serum levels. Clin Transplant 1992; 46: 468–472.Google Scholar
  76. 76.
    Alloway R, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO. Randomized double-blind study of standard versus low-dose OKT3 induction therapy in renal allograft recipients. Am J Kidney Dis 1993; 22: 36–43.PubMedGoogle Scholar
  77. 77.
    Hegewald M, O’Conell J, Renlund D et al. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation. J Heart Transplant 1989; 8: 303–310.PubMedGoogle Scholar
  78. 78.
    Kreis H, Chkoff N, Chatenoud L, Debure A, Lacombe M, Chretien Y, Legendre C, Caillat S, Bach JF. A randomized trial comparing the efficacy of OKT3 used to prevent or to treat rejection. Transplant Proc 1989; 21: 1741–1744.PubMedGoogle Scholar
  79. 79.
    Hirsch RL, Layton PC, Barnes LA, Kremer AB, Goldstein G. Orthoclone OKT3 treatment of acute renal allograft rejection in patients receiving maintenance cyclosporine therapy. Transplant Proc 1987.Google Scholar
  80. 80.
    Kreis H. Adverse events associated with OKT3 immunosuppression in the prevention or treatment of allograft rejection. Clin Transplantation 1993; 7: 431–446.Google Scholar
  81. 81.
    Van Wauwe J, De Mey J, Goossens J. OKT3:a monoclonal antibody with potent mitogenic properties. J Immunol 1980; 124: 2708–2713.PubMedGoogle Scholar
  82. 82.
    Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, De Pauw L, Wybran J, Kinnaert P, Dupont E, Toussaint C. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606–8.PubMedGoogle Scholar
  83. 83.
    Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, Franchimont P, Bach JF. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 1989; 320: 1420–1.PubMedGoogle Scholar
  84. 84.
    Bloemena E, ten Berge IJM, Surachno J, Wilmink JM. Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients. Transplantation 1990; 50: 330–331.PubMedGoogle Scholar
  85. 85.
    Gaston RS, Deierhoi MH, Patterson T, Prasthofer E, Julian BA, Barber WH, Laskow DA, Diethelm AG, Curtis JJ. OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int 1991; 39: 141–148.PubMedGoogle Scholar
  86. 86.
    Goldman M, Gérard C, Abramowicz D, Schandené L, Durez P, De Pauw L, Kinnaert P, Vereerstraeten P, Velu T. Induction of interleukin-6 and interleukin-10 by the OKT3 monoclonal antibody: possible relevance to posttransplant lymphoproliferative disorders. Clin Transplant 1992; 6: 265–268.Google Scholar
  87. 87.
    Ferran C, Dautry F, Merite S, Sheehan K, Schreiber R, Grau G, Bach JF, Chatenoud L. Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J Clin Invest 1994; 93: 2189–96.PubMedGoogle Scholar
  88. 88.
    Alegre M, Vandenabeele P, Flamand V, Moser M, Leo O, Abramowicz D, Urbain J, Fiers W, Goldman M. Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. Eur J Immunol 1990; 20: 707–10.PubMedGoogle Scholar
  89. 89.
    Ferran C, Dy M, Sheehan K, Schreiber R, Grau G, Bluestone J, Bach JF, Chatenoud L. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway. Eur J Immunol 1991; 21: 2349–53.PubMedGoogle Scholar
  90. 90.
    Matthys P, Dillen C, Proost P, Heremans H, Van DJ, Billiau A. Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-gamma or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine levels. Eur J Immunol 1993; 23: 2209–16.PubMedGoogle Scholar
  91. 91.
    Bûsing M, Meliert J, Greger B, Hopt U. Acute pulmonary insufficiency due to OKT3 therapy. Transplant Proc 1990; 22: 1779.PubMedGoogle Scholar
  92. 92.
    Waid TH, Lucas BA, Thompson JS, Brown SA, Munch L, Prebeck RJ, Jezek D. Treatment of acute cellular rejection with T10B9. 1A-31 or OKT3 in renal allograft recipients. Transplantation 1992; 53: 80–6.PubMedGoogle Scholar
  93. 93.
    Alegre ML, Vandenabeele P, Depierreux M, Florquin S, Deschodt Lanckman M, Flamand V, Moser M, Leo O, Urbain J, Fiers W, Goldman M. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone. J Immunol 1991; 146: 1184–91.PubMedGoogle Scholar
  94. 94.
    Norman D, Chatenoud L, Cohen D, Goldman M, Shield C. Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc 1993; 25: 89–92.PubMedGoogle Scholar
  95. 95.
    Doutrelepont JM, Abramowicz D, Borre B, Lemoine A, De PL, Kinnaert P, Vereerstraeten P, Vanherweghem JL, Goldman M. Prophylactic OKT3: practical considerations for the prevention of first-dose reactions. Transplant Proc 1993;.Google Scholar
  96. 96.
    Alegre ML, Gastaldello K, Abramowicz D, Kinnaert P, Vereerstraeten P, De PL, Vandenabeele P, Moser M, Leo O, Goldman M. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 1991; 52: 674–9.PubMedGoogle Scholar
  97. 97.
    Schandene L, Vandenbussche P, Crusiaux A, Alegre ML, Abramowicz D, Dupont E, Content J, Goldman M. Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells. Immunology 1992; 76: 30–4.PubMedGoogle Scholar
  98. 98.
    Schandene L, Gerard C, Crusiaux A, Abramowicz D, Velu T, Goldman M. Interleukin-10 inhibits OKT3-induced cytokine release: in vitro comparison with pentoxifylline. Transplant Proc 1993; 25: 55–56.PubMedGoogle Scholar
  99. 99.
    Leimenstoll G, Zabel P, Schroeder P, Schlaak M, Niedermayer W. Suppression of OKT3-induced tumor necrosis factor alpha formation by pentoxifylline in renal transplant recipients. Transplant Proc 1993; 25: 561–563.PubMedGoogle Scholar
  100. 100.
    Abramowicz D, Pradier O, Schandene L, Crusiaux A, De Pauw L, Vanherweghem J, Capel P, Kinnaert P, Vereerstraeten P, Goldman M. Pentoxifylline prevents TNF production and activation of coagulation induced by OKT3 in vitro but not in vivo. J Am Soc Nephrol 1993; 4: 921.Google Scholar
  101. 101.
    Vincenti FG, Vasconcelos M, Birnbaum JL, Tomlanovich SJ, Amend WJ, Melzer JS, Snyder JP. Pentoxifylline reduces the first-dose reactions following OKT3. Transplant Proc 1993; 25: 57–59.PubMedGoogle Scholar
  102. 102.
    DeVault GJ, Kohan DE, Nelson EW, Holman JJ. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3. Transplantation 1994; 57: 532–40.PubMedGoogle Scholar
  103. 103.
    Richard EA, Lorber MI, Marks WH, Bia MJ. Are calcium channel blockers protective against first-dose reactions to OKT3? Transplantation 1992; 54: 372–4.PubMedGoogle Scholar
  104. 104.
    Howard M, Ogarra A, Ishida H, Malefyt RD, Devries J. Biological Properties of Interleukin-10. J Clin Immunol 1992; 12: 239–247.PubMedGoogle Scholar
  105. 105.
    Donckier V, Flament V, Gerard C, Abramowicz D, Vandenabeele P, Wissing M, Delvaux A, Fiers W, Leo O, Velu T et al. Modulation of the release of cytokines and reduction of the shock syndrome induced by anti-CD3 monoclonal antibody in mice by interleukin-10. Transplantation 1994; 57: 1436–9.PubMedGoogle Scholar
  106. 106.
    Delvaux A, Donckier V, Bruyns C, Florquin S, Gerard C, Amraoui Z, Abramowicz D, Goldman M, Velu T. Effects of systemic administration of rIL-10 in an in vivo model of alloreactivity. Transplantation 1994; In press:.Google Scholar
  107. 107.
    Charpentier B, Hiesse C, Lantz O, Ferran C, Stephens S, O’Shaugnessy D, Bodmer M, Benoit G, Bach JF, Chatenoud L. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 1992; 54: 997–1002.PubMedGoogle Scholar
  108. 108.
    Shield C3, Kahana L, Pirsch J, Vergne MP, First MR, Schroeder TJ, Cohen D, Norman DJ, Monaco A, Martinez A et al. Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection. Transplantation 1992; 54: 164–6.PubMedGoogle Scholar
  109. 109.
    First MR, Schroeder TJ, Hariharan S, Weiskittel P. Reduction of the initial febrile response to OKT3 with indomethacin. Transplant Proc 1993.Google Scholar
  110. 110.
    Chan G, Weinstein S, Wright C, Bowers V, Alveranga D, Shires D, Ackerman J, Lefor W, Kahana L. Encephalopathy associated with OKT3 administration. Possible interactions with indomethacin. Transplantation 1991; 52: 148–150.PubMedGoogle Scholar
  111. 111.
    Toussaint C, De Pauw L, Vereerstraeten P, Kinnaert P, Abramowicz D, Goldman M. Possible nephrotoxicity of the prophylactic use of OKT3 monoclonal antibody after cadaveric renal transplantation. Transplantation 1989; 48: 524–6.PubMedGoogle Scholar
  112. 112.
    Goldman M, Abramowicz D, De Pauw L, Alegre ML, Widera I, Vereerstraeten P, Kinnaert P. OKT3-induced cytokine release attenuation by high-dose methylprednisolone [letter]. Lancet 1989; 2: 802–3.PubMedGoogle Scholar
  113. 113.
    Simpson MA, Madras PN, Cornaby AJ, Etienne T, Dempsey RA, Clowes GH, Monaco AP. Sequential determinations of urinary cytology and plasma and urinary lymphokines in the management of renal allograft recipients. Transplantation 1989; 47: 218–23.PubMedGoogle Scholar
  114. 114.
    Goldman M, Van LJ, Abramowicz D, De PL, Kinnaert P, Vereerstraeten P. Evolution of renal function during treatment of kidney graft rejection with OKT3 monoclonal antibody. Transplantation 1990; 50: 158–9.PubMedGoogle Scholar
  115. 115.
    Omitted in proofs.Google Scholar
  116. 116.
    Abramowicz D, Pradier O, Marchant A, Florquin S, De Pauw L, Vereerstraeten P, Kinnaert P, Vanherweghem JL, Goldman M. Induction of thromboses within renal grafts by high-dose prophylactic OKT. Lancet 1992; 339: 777–8.PubMedGoogle Scholar
  117. 117.
    Pradier O, Marchant A, Abramowicz D, De Pauw L, Vereerstraeten P, Kinnaert P, Vanherweghem JL, Capel P, Goldman M. Procoagulant effect of the OKT3 monoclonal antibody: involvement of tumor necrosis factor. Kidney Int 1992; 42: 1124–9.PubMedGoogle Scholar
  118. 118.
    Pradier O, Abramowicz D, Capel P, Goldman M. Procoagulant properties of OKT3 at the monocyte level: inhibition by pentoxifylline. Transplant Proc 1993.Google Scholar
  119. 119.
    Abramowicz D, Pradier O, De Pauw L, Kinnaert P, Mat O, Surquin M, Doutrelepont J, Vanherweghem J, Capel P, Vereerstraeten P, Goldman M. High-dose glucocorticosteroids increase the procoagulant effects of OKT3. Kidney Int 1994; In press.Google Scholar
  120. 120.
    Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514–1516.PubMedGoogle Scholar
  121. 121.
    Swinnen L, Costanzo-Nordin M, Fisher S, O’Sullivan E, Johnson M, Heroux A, Dizikes G, Pifarre R, Fisher R. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723–1728.PubMedGoogle Scholar
  122. 122.
    Abramowicz D, Goldman M, De Pauw L, Doutrelepont JM, Kinnaert P, Vanherweghem J, Vereerstraeten P. OKT3 and post-transplantation lymphoproliferative disorders. N Eng J Med 1991; 324: 1438–1439.Google Scholar
  123. 123.
    Norman DJ, Kahana L, Stuart F, Thistlethwaite RJ, Shield CF, Monaco A, Dehlinger J, Wu SC, Van Horn A, Haverty TP. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44–50.PubMedGoogle Scholar
  124. 124.
    Chatenoud L. Humoral immune response against OKT3. Transplant Proc 1993; 25: 68–73.PubMedGoogle Scholar
  125. 125.
    Chatenoud L. Immunologic monitoring during OKT3 therapy. Clin Transplant 1993; 7: 422–430.PubMedGoogle Scholar
  126. 126.
    Abramowicz D, Goldman M, Mat O, Estermans G, Crusiaux A, Vanherweghem J, De Pauw L, Kinnaert P, P V. OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients. Transplant Int 1994; 7: 258–263.Google Scholar
  127. 127.
    Kimball JA, Norman DJ, Shield CF, Schroeder TJ, Lisi P, Garovoy M, O’Connell JB, Stuart F, McDiarmid SV, Wall W. OKT3 antibody response study (OARS): a multicenter comparative study. Transplant Proc 1993.Google Scholar
  128. 128.
    Legendre C, Kreis H, Bach JF, Chatenoud L. Prediction of successful allograft rejection retreatment with OKT3. Transplantation 1992; 53: 87–90.PubMedGoogle Scholar
  129. 129.
    Chatenoud L, Bach JF. Therapeutic monoclonal antibodies in transplantation. Transplant Proc 1993; 25: 473–474.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1995

Authors and Affiliations

  • Daniel Abramowicz
  • Michel Goldman

There are no affiliations available

Personalised recommendations